Diplomat Pharmacy, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Cash flows from operating activities:
Net (loss) income
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization
Goodwill impairments
Impairments of definite-lived intangible assets
Share-based compensation expense
Net provision for doubtful accounts
Amortization of debt issuance costs
Impairment expense
Change in fair value of contingent consideration
Contingent consideration payments
Deferred income tax (benefit) expense
Equity loss and impairment of non-consolidated entities
Excess tax benefits related to share-based awards (Note 10)
Change in fair value of redeemable common shares
Termination of existing stock redemption agreement
Other
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable
Inventories
Accounts payable
Rebates payable
Other assets and liabilities

Net cash provided by operating activities
Cash flows from investing activities:
Payments to acquire businesses, net of cash acquired
Expenditures for property and equipment
Expenditures for capitalized software for internal use
Capital investments in and loans to non-consolidated entities
Net repayment (issuance) of related parties' notes receivable
Other
Net proceeds from sales of property and equipment
Net cash used in investing activities

Cash flows from financing activities:
Net (payments) borrowings from line of credit
Proceeds from long-term debt
Payments on long-term debt
Proceeds from initial public offering, net of issuance costs
Payments of debt issuance costs
Proceeds from issuance of stock upon stock option exercises
Contingent consideration payments
Proceeds from public offering, net of transaction costs
Payments made to repurchase stock options
Excess tax benefits related to share-based awards (Note 10)
Proceeds from sale of preferred stock, net of transaction costs
Payments made to repurchase common stock
Net (decrease) increase in cash and equivalents
Net cash (used in) provided by financing activities

Net (decrease) increase in cash and equivalents
Cash and equivalents at beginning of year
Cash and equivalents at end of year
Supplemental disclosures of cash flow information:
Issuance of common stock as partial consideration for a business acquisition
Removal of common stock redemption features
Cash paid for interest
Cash paid for income taxes

Comments